Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aminoglutethimide
Drug ID BADD_D00107
Description An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Indications and Usage For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.
Marketing Status approved; investigational
ATC Code L02BG01
DrugBank ID DB00357
KEGG ID D00574
MeSH ID D000616
PubChem ID 2145
TTD Drug ID D0M6DO
NDC Product Code Not Available
UNII 0O54ZQ14I9
Synonyms Aminoglutethimide | Cytadren | Orimeten
Chemical Information
Molecular Formula C13H16N2O2
CAS Registry Number 125-84-8
SMILES CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Leukopenia01.02.02.001---
Malaise08.01.01.003--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Nervousness19.06.02.003---
Neuropathy peripheral17.09.03.003---
Neutropenia01.02.03.004---
Pancytopenia01.03.03.003---
Pruritus23.03.12.001--
Rash23.03.13.001---
Rhabdomyolysis15.05.05.002--
Seizure17.12.03.001--
Shock24.06.02.002---
Sinus tachycardia02.03.03.010--
Skin disorder23.03.03.007---
Somnolence17.02.04.006; 19.02.05.003--
Supraventricular tachycardia02.03.03.012--
Tachycardia02.03.02.007---
Tremor17.01.06.002--
Urticaria10.01.06.001; 23.04.02.001--
Vascular resistance systemic13.14.03.019---
Ventricular arrhythmia02.03.04.006--
Ventricular extrasystoles02.03.04.007---
Virilism05.05.01.001; 21.10.04.001--
Vomiting07.01.07.003--
Haemodynamic instability24.03.02.006---
Musculoskeletal discomfort15.03.04.001---
Precocious puberty05.05.03.001; 21.03.02.009--
Decreased appetite08.01.09.028; 14.03.01.005--
Pulmonary toxicity12.03.01.013; 22.01.02.007---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene